This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Current and future therapy for malignant pleural effusion
Chest. 1992 ;103(1 SUPPL.)
AbstractSeveral options are available for treatment of malignant pleural effusions in patients with non-small-cell lung cancer. Repeat thoracentesis may be appropriate for the patient with limited survival and a slowly recurrent effusion. Pleurodesis with a sclerosing agent administered via a chest tube is the most widely used therapy, though controversy exists as to which drug produces the best results. Pleuroperitoneal shunting remains an option for those patients whose lung is trapped by tumor. Video-assisted thoracoscopy is likely to change the treatment patterns of malignant pleural effusion. Thoracoscopic pleurectomy can be performed with minimal morbidity. Alternatively, sclerosing agents such as talc can be easily and uniformly introduced into the thoracic cavity under thoracoscopic control. Future therapy is likely to entail a diagnostic thoracentesis followed by a definitive thoracoscopic procedure.
Notes00123692 (ISSN) Cited By: 26; Export Date: 31 May 2006; Source: Scopus CODEN: CHETB Language of Original Document: English Correspondence Address: Keller, S.M.; Department of Surgical Oncology; Fox Chase Cancer Center; 7701 Burholme Avenue Philadelphia, PA 19111, United States Chemicals/CAS: bleomycin, 11056-06-7; chlormethine, 51-75-2, 55-86-7, 82905-71-3; doxorubicin, 23214-92-8, 25316-40-9; mepacrine, 69-05-6, 83-89-6; talc, 14807-96-6; tetracycline, 23843-90-5, 60-54-8, 64-75-5, Sclerosing Solutions